Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationAudience · ordering and interpretation
For Clinicians
A decision-ready report: ranked, evidenced, and co-signed by a molecular tumour board, so you can act on your patient’s biology without wading through variant tables.
01Ordering and interpretation
Time and certainty, given back
We do the interpretive heavy lifting and deliver a decision-ready report: ranked, evidenced, and co-signed by a molecular tumour board.
You remain the treating clinician. We are the second set of expert eyes.
Image placeholder
An oncologist reading the one-page summary
02
The decision, made faster
Every report opens with a one-page Chief Oncologist Summary built to be read in under a minute: Actionability Index, recommended first-line direction, explicit contraindications, and urgent flags.
Beneath it sits the full evidence, with variants tiered against AMP/ASCO/CAP, ESCAT and OncoKB, and a concordance view showing where frameworks agree.
Ranked therapy options
With the rationale and evidence tier for each.
Explicit contraindications
What this tumour will resist, stated plainly.
Matched clinical trials
For the exact molecular profile.
Biosimilar and access mapping
For the Indian context.
Pharmacogenomics
To dose safely and avoid severe adverse reactions.
Monitoring built in
Serial ctDNA and MRD escalate findings back to you.
03
Accountability, answered cleanly
Software informs. A clinician decides.
Every clinically consequential statement is authored and signed by a licensed molecular tumour board through KPCIRC. Our engine annotates, matches and models. It does not diagnose or prescribe, and it never has the final word.
That is deliberate. It gives you a defensible, human-authored decision and a named clinical partner to discuss it with.
04
Ordering and sample logistics
- Step 1Refer or order
We advise on the right tier for your question.
- Step 2Sample handled
Home or in-clinic phlebotomy, or retrieval of an existing block.
- Step 3Sequencing and engine
Accredited sequencing, then interpretation.
- Step 4Tumour board sign-out
The board reviews, authors and signs.
- Step 5Report and discussion
You can request a board discussion or second opinion.
05
Tumour board access and research
Case discussion
Through KPCIRC you can request a molecular tumour board discussion of a specific case, on a paid basis.
Independent second opinion
The same authority that signs our reports, available directly when a case is complex.
Contribute to research
With appropriate consent, ordering can contribute de-identified data to research that improves interpretation for the next patient. Participation is optional.
Accreditation and methods
How your patient’s result is produced
Sequencing and variant calling are performed by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines, using a CE-IVD certified variant database for classification and reporting.
The OnKommon engine adds biomarker matching, modelling and the intelligence layers, and is provided for research and decision-support use. It does not make a diagnosis. Every report discloses panel scope, per-gene coverage, tumour fraction and limitations.
CAPaccredited laboratory partner
ISO 15189laboratory quality standard
CE-IVDcertified variant database
3evidence frameworks applied
Research and evidence
The science behind this
Comprehensive profiling reviewed by a molecular tumour board rests on a substantial peer-reviewed evidence base.
Study 1
Tumour-board-guided matched therapy
Across 715 advanced-cancer patients, closer matching between therapy and molecular profile on board advice was associated with improved response and survival.
Kato S, et al. Nature Communications, 2020.
Study 2
Liquid-biopsy profiling is guideline-supported
NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue. ASCO recommends blood cfDNA for comprehensive profiling in advanced breast cancer.
Review, Cancers, 2022.
Study 3
Plasma genotyping increases matched therapy
Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients on matched therapy.
Aggarwal C, et al. JAMA Oncology, 2019.
These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.
Being clear about our limits
What we do and do not do
What we DO
- Deliver a ranked, evidence-tiered, board-signed report
- Grade variants against AMP/ASCO/CAP, ESCAT and OncoKB
- Flag contraindications, trials, biosimilars and pharmacogenomics
- Offer serial monitoring and second-opinion board access
What we DON’T do
- Diagnose or prescribe, you retain clinical responsibility
- Claim autonomous, AI-only decision-making
- Guarantee drug availability, approval, cover or efficacy
- Replace confirmatory or companion diagnostic testing
Plain-language glossary (6 terms)
| Term | What it means |
|---|---|
| MTB | Molecular tumour board, the licensed panel that signs the report. |
| CGP | Comprehensive genomic profiling, reading many cancer genes in one test. |
| ESCAT | The ESMO scale for how ready a molecular target is to guide treatment. |
| OncoKB levels | A scale grading therapeutic actionability by level of evidence. |
| AMP/ASCO/CAP tiers | The framework grading clinical significance of somatic variants. |
| MRD | Molecular residual disease, microscopic disease left after treatment. |
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal